The other shoe finally dropped this week in the lucrative weight-loss market, with the FDA’s much-anticipated approval of Eli Lilly’s obesity drug Zepbound (tirzepatide). The regulatory decision on Wednesday cleared tirzepatide, which was previously approved for type 2 diabetes as Mounjaro, under the brand name Zepbound to treat obesity and overweight patients who also have weight-related medical problems such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,